About 26S proteasome regulatory subunit 8
26S proteasome regulatory subunit 8 (PSMC5) is a protein
from Homo sapiens identified by UniProt accession
P62195, 406 residues long.
MolForge cross-references it against 0 known binders and
85 disease associations.
Target properties
| Protein name | 26S proteasome regulatory subunit 8 |
| UniProt accession | P62195 |
| Gene | PSMC5 |
| Organism | Homo sapiens |
| Length | 406 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (85)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.46
- neurodegenerative disease · score 0.31
- ovarian cancer · score 0.29
- chronic lymphocytic leukemia · score 0.28
- head and neck squamous cell carcinoma · score 0.28
- squamous cell lung carcinoma · score 0.28
- clear cell renal carcinoma · score 0.27
- gastric adenocarcinoma · score 0.27
- multiple myeloma · score 0.24
- hemoglobin measurement · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P62195-F1 | alphafold | PREDICTED | 82.15 | — |
Amino-acid sequence (406 residues)
MALDGPEQME LEEGKAGSGL RQYYLSKIEE LQLIVNDKSQ NLRRLQAQRN ELNAKVRLLR EELQLLQEQG SYVGEVVRAM DKKKVLVKVH PEGKFVVDVD KNIDINDVTP NCRVALRNDS YTLHKILPNK VDPLVSLMMV EKVPDSTYEM IGGLDKQIKE IKEVIELPVK HPELFEALGI AQPKGVLLYG PPGTGKTLLA RAVAHHTDCT FIRVSGSELV QKFIGEGARM VRELFVMARE HAPSIIFMDE IDSIGSSRLE GGSGGDSEVQ RTMLELLNQL DGFEATKNIK VIMATNRIDI LDSALLRPGR IDRKIEFPPP NEEARLDILK IHSRKMNLTR GINLRKIAEL MPGASGAEVK GVCTEAGMYA LRERRVHVTQ EDFEMAVAKV MQKDSEKNMS IKKLWK
Explore 26S proteasome regulatory subunit 8 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets